Chemotherapy of Osteosarcoma

  • Stefano Ferrari
  • Emanuela PalmeriniEmail author


Treatment of osteosarcoma requires a combined approach of surgery of the primary tumor and systemic chemotherapy.


Multimodal treatment Neoadjuvant chemotherapy Clinical studies Chemotherapy-induced necrosis doxorubicin methotrexate cisplatin ifosfamide 


  1. 1.
    Campanacci M. High grade osteosarcomas. In: Campanacci M, editor. Bone and soft tissue tumors. 2nd ed. New York: Springer; 1999. p. 463–515.CrossRefGoogle Scholar
  2. 2.
    Rosen G, Caparros B, Huvos A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–30.CrossRefGoogle Scholar
  3. 3.
    Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–61.CrossRefGoogle Scholar
  4. 4.
    Denecke T, Hundsdörfer P, Misch D, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging. 2010;37(10):1842–53.CrossRefGoogle Scholar
  5. 5.
    Palmerini E, Colangeli M, Nanni C, et al. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging. 2017;44(2):215–23.CrossRefGoogle Scholar
  6. 6.
    Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005;65:8142–50.CrossRefGoogle Scholar
  7. 7.
    Whelan JS, Jinks RC, McTiernan A, et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol. 2012;23(6):1607–16.CrossRefGoogle Scholar
  8. 8.
    Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.CrossRefGoogle Scholar
  9. 9.
    Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893–9.CrossRefGoogle Scholar
  10. 10.
    Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–52.CrossRefGoogle Scholar
  11. 11.
    Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11.CrossRefGoogle Scholar
  12. 12.
    Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, Egeler RM. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47(16):2431–45.CrossRefGoogle Scholar
  13. 13.
    Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30(17):2112–8.CrossRefGoogle Scholar
  14. 14.
  15. 15.
    Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus map alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33(20):2279–87.CrossRefGoogle Scholar
  16. 16.
    Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–408.CrossRefGoogle Scholar
  17. 17.
    Piperno-Neumann S, Le Deley MC, Rédini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1070–80.CrossRefGoogle Scholar
  18. 18.
    Gaspar N, Occean BV, Pacquement H, et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J Cancer. 2018;88:57–66. Epub 2017 Nov 28.CrossRefPubMedGoogle Scholar
  19. 19.
    Ferrari S, Bielack SS, Smeland S, et al. EURO-B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma. Tumori. 2018;104(1):30–6.CrossRefGoogle Scholar
  20. 20.
    Longhi A, Bielack SS, Grimer R, et al. Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer. 2017;74:9–16.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Chemotherapy UnitIRCCS Istituto Ortopedico RizzoliBolognaItaly
  2. 2.Department of Experimental, Diagnostic and Specialty Medicine (DIMES)University of BolognaBolognaItaly

Personalised recommendations